Valuation: Exelixis, Inc.

Market Cap 17.22B 15.44B 14.23B 12.93B 24.47B 1,615B 25.15B 170B 67.9B 865B 64.63B 63.26B 2,735B P/E 2026 *
20.5x
P/E 2027 * 17.4x
Enterprise Value 16.28B 14.6B 13.45B 12.22B 23.13B 1,526B 23.77B 161B 64.18B 818B 61.09B 59.8B 2,585B EV / Sales 2026 *
6.37x
EV / Sales 2027 * 5.38x
Free-Float
98.13%
Yield 2026 *
-
Yield 2027 * -
1 day-1.62%
1 week-2.39%
Current month+1.71%
1 month+17.91%
3 months+33.27%
6 months+46.55%
Current year+61.03%
1 week 68.01
Extreme 68.01
73.69
1 month 58.59
Extreme 58.59
73.69
Current year 39.71
Extreme 39.71
73.69
1 year 39.71
Extreme 39.71
73.69
3 years 19.2
Extreme 19.2
73.69
5 years 14.87
Extreme 14.87
73.69
10 years 13.42
Extreme 13.42
73.69
Manager TitleAgeSince
Chief Executive Officer 65 21/07/2010
Director of Finance/CFO 58 14/07/2015
Chief Operating Officer 63 31/01/2016
Director TitleAgeSince
Director/Board Member 70 31/01/2004
Director/Board Member 82 31/07/2004
Chairman 77 31/12/1997
Date Insider Type Main position Quantity % Market Cap. Importance
10/08/26 Sell

Director

-9,812 0.0039%
01/06/26 Sell

Director

-9,812 0.0039%
01/06/26 Sell

Director

-3,925 0.0016%
Change 5-day change 1-year change 3-year change Capi.($)
-1.62%-2.39%+70.44%+236.10% 17.22B
+0.01%+11.10%+60.83%+70.43% 68.32B
+0.53%+6.63%+13.95%+88.87% 60.26B
+0.42%+1.35%+23.78%+97.55% 55.86B
+1.60%+19.44%+28.80%+112.95% 48.43B
-1.32%+4.78%+29.15%+40.40% 45.34B
-3.54%-0.60%+207.76%+879.50% 41.76B
-3.33%+6.90%+22.78%+48.07% 34.5B
+0.28%-3.71%+90.94%+66.33% 33.8B
-1.81%+0.79%+46.51%-0.20% 25.96B
Average -0.86%+4.62%+59.49%+164.00% 43B
Weighted average by Cap. -0.58%+4.94%+55.62%+156.69%

Financials

2026 *2027 *
Net sales 2.56B 2.29B 2.11B 1.92B 3.63B 240B 3.73B 25.29B 10.08B 128B 9.59B 9.39B 406B 2.88B 2.58B 2.38B 2.16B 4.09B 270B 4.2B 28.46B 11.34B 144B 10.79B 10.57B 457B
Net income 895M 803M 740M 672M 1.27B 83.92B 1.31B 8.86B 3.53B 44.96B 3.36B 3.29B 142B 1.02B 916M 844M 767M 1.45B 95.77B 1.49B 10.11B 4.03B 51.31B 3.83B 3.75B 162B
Net Debt -943M -846M -780M -708M -1.34B -88.44B -1.38B -9.33B -3.72B -47.38B -3.54B -3.46B -150B -1.74B -1.56B -1.44B -1.31B -2.47B -163B -2.54B -17.23B -6.86B -87.46B -6.53B -6.4B -276B
Projected Income Statement - Annual - Exelixis, Inc.
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Employees
1,077
Date Price Change Volume
10/11/26 US$70.58 -1.62% 5,583,516
09/11/26 US$71.74 +3.12% 4,826,248
06/11/26 US$69.57 +1.25% 2,003,609
05/11/26 US$68.71 -5.55% 4,376,151
04/11/26 US$72.75 +0.61% 3,014,149
Trader
Investor
Global
Quality
ESG MSCI
BB
MarketScreener Ratings - Exelixis, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
70.58USD
Average target price
61.57USD
Spread / Average Target
-12.76%
  1. Stock Market
  2. Stocks
  3. EXEL Stock